Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers

Conditions

Malignant Solid Tumor, Metastatic EphA2 Positive Cancer

Keywords

EphA2 positive cancer, DS-8895a monoclonal antibody

Brief summary

This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers. The primary study objective was to determine the safety of DS-8895a, with secondary objectives of determining the biodistribution, tumor uptake (bioimaging), pharmacokinetics (PK), antitumor and pharmacodynamic response, and correlations between pharmacodynamics and clinical outcomes, as appropriate.

Detailed description

Patients received an initial \^89Zr trace-labelled infusion of DS-8895a on Day 1, followed by safety assessments, positron emission tomography (PET) imaging, and PK sampling over a 1-week period. DS-8895a was infused again on Days 8, 22, and 36. The Day 36 infusion of DS-8895a was also trace labelled with \^89Zr, with subsequent PET imaging and PK sampling. Four dose levels (1, 3, 10 and 20 mg/kg) were to be evaluated, with 3 to 6 patients entered at each dose level. Patients who responded or had stable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression, with restaging performed by computed tomography (CT) scans every 6 weeks.

Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM.

2022-04-1118 citations

10.1007/s10637-022-01237-3

Interventions

DRUGDS-8895a 1 mg/kg

Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.

DRUGDS-8895a 3 mg/kg

Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.

DRUGDS-8895a 10 mg/kg

Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.

Study design

Allocation

NA

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Patients were enrolled in sequential cohorts following a 3+3 dose-escalation scheme.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Advanced or metastatic EphA2 positive cancer (based on immunohistochemistry of archived or fresh tumor tissue). 2. Malignant tumor that was refractory to standard treatment. 3. At least one reference tumor \> 1 cm in size for assessment of tumor uptake of \^89Zr-Df-DS-8895a. 4. Expected survival of at least 3 months. 5. Eastern Cooperative Oncology Group performance status ≤ 1. 6. Within the last week prior to the first study drug administration, laboratory parameters for vital functions were to be in the normal range. Out-of-range values that were not clinically significant were permitted, except that the following parameters were to be in the specified ranges: * Neutrophil count ≥ 1.5 x 10\^9/L * Platelet count ≥ 90 x 10\^9/L * International normalized ratio ≤ 1.5 * Serum aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the upper limit of normal (ULN); ≤ 5 x ULN if liver metastases * Serum bilirubin ≤ 1.5 x ULN 7. Calculated creatinine clearance ≥ 55 mL/min. 8. Age ≥ 18 years. 9. Able and willing to give valid written informed consent.

Exclusion criteria

1. Active central nervous system metastases. Definitively treated metastases were allowed if stable for 6 weeks off therapy. 2. Known immunodeficiency or human immunodeficiency virus positivity. 3. Serious illnesses, e.g., serious infections requiring antibiotics, bleeding disorders, or any condition that in the opinion of the Investigator would have interfered with the ability of the patient to fulfill the study requirements. 4. Other malignancy, apart from non-melanoma skin cancer, within 3 years prior to the first study drug administration that in the opinion of the investigator had \> 10% risk of relapse within 12 months. 5. Significant allergic reaction to prior antibody infusions. 6. Chemotherapy, radiotherapy, or investigational agent within 4 weeks prior to the first study drug administration. 7. Regular corticosteroid, non-steroidal anti-inflammatory drug (other than paracetamol or low-dose aspirin) or other immunosuppressive treatment within 3 weeks prior to the first study drug administration (intermittent dosing permitted if less than 4 doses within a 3-day period). 8. Mental impairment that could have compromised the ability to give informed consent and comply with the requirements of the study. 9. Lack of availability for clinical follow-up assessments. 10. Pregnancy or breastfeeding. 11. Women of childbearing potential: Refusal or inability to use effective means of contraception.

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients With Treatment-emergent Adverse Events	Continuously for up to 58 weeks	Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Treatment-emergent adverse events (TEAEs) were reported based on clinical laboratory tests, physical examinations, and vital signs from pre-treatment through the study period.

Secondary

Measure	Time frame	Description
Number of Patients With Best Overall Tumor Response	Up to 58 weeks	Tumor responses were evaluated using computed tomography and categorized according to the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) at Screening (up to 21 days before the first dose of study drug), on Day 50, and approximately every 6 weeks thereafter for patients who received continued study dosing. Per RECIST, target lesions are categorized as follows: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD): ≥ 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria.
Mean Area Under the Serum Concentration Curve of ^89Zr-Df-DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The pharmacokinetics (PK) of \^89Zr-Df-DS-8895a were calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Volume of Distribution at Steady State of ^89Zr-Df-DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of \^89Zr-Df-DS-8895a was calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Total Serum Clearance of ^89Zr-Df-DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of \^89Zr-Df-DS-8895a was calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Maximum Serum Concentration of ^89Zr-Df-DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of \^89Zr-Df-DS-8895a was calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Elimination Half-life of ^89Zr-Df-DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of \^89Zr-Df-DS-8895a was calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Number of Patients With Tumor Uptake of ^89Zr-Df-DS-8895a	Up to Day 43	The biodistribution and tumor uptake of \^89Zr-Df-DS-8895a was determined based on qualitative analysis of whole body positron emission tomography (PET)/computed tomography (CT) images. PET imaging was performed following the \^89Zr-Df-DS-8895a infusions on Day 1 (Days 1, 4/5, and 7/8) and Day 36 (Days 36, 39/40 and 42/43). Qualitative parameters assessed included tumor uptake of reference lesions (scored on a 0-3 point scale: none, low, med, high). The reference lesions were initially identified on fluorodeoxyglucose (FDG) PET scans with a score of 3 for \[18F\]-fluorodeoxyglucose uptake. The summary table presents the maximum reference lesion \^89Zr-Df-DS-8895a uptake score reported for individual patients.
Mean Volume of Distribution at Steady State of DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of DS-8895a was calculated based on data from enzyme-linked immunosorbent assay (ELISA) of serum samples. Serum samples for ELISA were drawn at the same times as for gamma counting with the addition of Day 8 (pre- and 0 to 30 minutes post-infusion), Day 9 (anytime), and Day 22 (pre- and 0 to 30 minutes post-infusion). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Total Serum Clearance of DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of DS-8895a was calculated based on data from enzyme-linked immunosorbent assay (ELISA) of serum samples. Serum samples for ELISA were drawn at the same times as for gamma counting with the addition of Day 8 (pre- and 0 to 30 minutes post-infusion), Day 9 (anytime), and Day 22 (pre- and 0 to 30 minutes post-infusion). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Maximum Serum Concentration of DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of DS-8895a was calculated based on data from enzyme-linked immunosorbent assay (ELISA) of serum samples. Serum samples for ELISA were drawn at the same times as for gamma counting with the addition of Day 8 (pre- and 0 to 30 minutes post-infusion), Day 9 (anytime), and Day 22 (pre- and 0 to 30 minutes post-infusion). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Mean Elimination Half-life of DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of DS-8895a was calculated based on data from enzyme-linked immunosorbent assay (ELISA) of serum samples. Serum samples for ELISA were drawn at the same times as for gamma counting with the addition of Day 8 (pre- and 0 to 30 minutes post-infusion), Day 9 (anytime), and Day 22 (pre- and 0 to 30 minutes post-infusion). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.
Number of Patients With Pharmacodynamic (Metabolic) Response	Day 29 and Day 50	The pharmacodynamic (metabolic) response of DS-8895a was assessed by \^18F-FDG PET at Screening, Day 29, and Day 50. Tumor metabolism response was evaluated as the difference in standardized uptake values between the pre- and post-treatment FDG PET scans. The measurement of \[18F\]-FDG uptake for tumor metabolic response monitoring was performed according to the European Organization for Research and Treatment of Cancer (EORTC) PET response criteria (Young et al. Eur J Cancer 1999;35:1773-82).
Number of Patients With Human Anti-Human Antibody Positivity	Up to 43 Weeks	Blood samples to detect human anti-human antibody (HAHA) formation were collected on Days 1 (pre-infusion \[within 7 days of Day 1 dose\] and post-infusion), 8, 22, 36 (pre-infusion), and 50 (anytime). For Cycle 2 onward, HAHA samples were collected on Day 1 (pre-infusion) and at the end of the study (anytime). HAHA samples were analyzed using ELISA and were categorized as either positive or negative for a HAHA response. HAHA positivity indicates that a patient has developed an antibody response.
Mean Area Under the Serum Concentration Curve of DS-8895a Following the First Infusion	Cycle 1 Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion)	The PK of DS-8895a was calculated based on data from enzyme-linked immunosorbent assay (ELISA) of serum samples. Serum samples for ELISA were drawn at the same times as for gamma counting with the addition of Day 8 (pre- and 0 to 30 minutes post-infusion), Day 9 (anytime), and Day 22 (pre- and 0 to 30 minutes post-infusion). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.

Countries

Australia

Participant flow

Participants by arm

Arm	Count
DS-8895a 1 mg/kg Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.	4
DS-8895a 3 mg/kg Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.	3
Total	7

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Adverse Event	0	1	0
Overall Study	Progressive disease	3	2	0
Overall Study	Serious Adverse Event During Screening	1	0	1
Overall Study	Withdrawal by Subject	1	0	0

Baseline characteristics

Characteristic	DS-8895a 1 mg/kg	DS-8895a 3 mg/kg	Total
Age, Continuous	67.3 years STANDARD_DEVIATION 7.4	64.0 years STANDARD_DEVIATION 15.1	65.9 years STANDARD_DEVIATION 10.3
Body Mass Index	24.4 kg/m^2 STANDARD_DEVIATION 4.2	28.1 kg/m^2 STANDARD_DEVIATION 6.4	26.0 kg/m^2 STANDARD_DEVIATION 5.1
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants	3 Participants	7 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) White	4 Participants	2 Participants	6 Participants
Region of Enrollment Australia	4 Participants	3 Participants	7 Participants
Sex: Female, Male Female	1 Participants	1 Participants	2 Participants
Sex: Female, Male Male	3 Participants	2 Participants	5 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	1 / 5	1 / 3	0 / 1
other Total, other adverse events	5 / 5	3 / 3	1 / 1
serious Total, serious adverse events	1 / 5	1 / 3	1 / 1

Outcome results

Primary

Number of Patients With Treatment-emergent Adverse Events

Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Treatment-emergent adverse events (TEAEs) were reported based on clinical laboratory tests, physical examinations, and vital signs from pre-treatment through the study period.

Time frame: Continuously for up to 58 weeks

Population: The Safety Analysis Set comprised all patients who received at least 1 infusion of DS-8895a.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 5 TEAE	0 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Treatment-related TEAE	0 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Treatment-emergent Serious Adverse Event	0 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	TEAE leading to study withdrawal	0 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Any TEAE	4 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 1 TEAE	0 Participants
DS-8895a 1 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 2 TEAE	4 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 5 TEAE	1 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Any TEAE	3 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Treatment-related TEAE	0 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 2 TEAE	1 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Treatment-emergent Serious Adverse Event	1 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	Maximum grade 1 TEAE	1 Participants
DS-8895a 3 mg/kg	Number of Patients With Treatment-emergent Adverse Events	TEAE leading to study withdrawal	1 Participants

Secondary

Mean Area Under the Serum Concentration Curve of ^89Zr-Df-DS-8895a Following the First Infusion

The pharmacokinetics (PK) of \^89Zr-Df-DS-8895a were calculated based on data from gamma counting of serum samples. Serum samples for gamma counting were drawn on Day 1 (pre-infusion and 5 minutes, 1, 2, and 4 hours post-infusion), Day 2 (24 hours post-infusion), Day 4/5 (anytime), Day 36 (pre-infusion, and 5 minutes, 1, 2, and 4 hours post infusion), Day 37 (24 hours post-infusion), Day 39/40 (anytime), Day 42/43 (anytime), and Day 50 (anytime). For Cycle 2 onward, blood samples for PK were taken at pre- and 0 to 30 minutes post-infusion on Days 1, 15, and 29.